



MOREPEN



Date: 24/04/2025

To,

National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai- 400 051
Symbol: MOREPENLAB

BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai- 400 001
Scrip Code: 500288

Subject: Launch of four new products “Ticapen, UdoFix, LycoMore, Acifix”

Ref.: Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)

Dear Sir/ Madam,

Pursuant to Regulation 30 of the SEBI Listing Regulations, 2015, we would like to inform the launch of four new products, *namely* **Ticapen, UdoFix, LycoMore, and Acifix** by the Company.

The necessary information regarding the aforesaid product launch, including disclosures as required under the SEBI Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, is given in the ‘Annexure’ titled ‘**Morepen Doubles Down on Rx Innovation**’.

This is for your information and dissemination on your website.

Thanking you,

Yours faithfully,

For Morepen Laboratories Limited

Vipul Kumar Srivastava
Company Secretary
F-12148

Encl.: a/a.

Morepen Laboratories Limited

CIN NO. L24231 HP1984PLC006028

Corp. Off.: 2nd Floor, Tower C, DLF Cyber Park, Udyog Vihar-III, Sector-20, Gurugram, Haryana-122016, INDIA
TEL.: +91 124 4892000, E-mail: corporate@morepen.com, Website: www.morepen.com

Regd. Off.: Morepen Village, Malkumajra, Nalagarh Road, Baddi, Distt. Solan (H.P.) -173205, INDIA
Tel.: +91 1795 266401-03, 244590, Fax: +91 1795 244591, E-mail: plants@morepen.com


Morepen Double Down on Rx Innovation

Morepen Laboratories is pleased to announce the launch of four new products—**Ticapen, UdoFix, LycoMore, Acifix** in the month of April 2025 to cater the domestic market in addition to **Empamore** launched last month continuing its commitment to offer innovative latest products marking an another milestone reinforcing the doctor and patient trust. These new launches reflect our unwavering focus on **research-led innovation, clinical excellence, and affordable healthcare access**, addressing critical needs in **cardiology, hepatology, nutrition, and diabetology**.

This strategic expansion reinforces Morepen's commitment to **scaling its finished dosages business** while continuing to invest in **cutting-edge R&D** that powers a robust pipeline of differentiated, high-quality medicines. Importantly, **all APIs used in these products are manufactured in-house** by Morepen at its **world-class, USFDA-approved plants**, ensuring consistent quality and supply chain control.

As **India's #1 exporter of APIs** for six globally used molecules—**Loratadine, Montelukast, Desloratadine, Atorvastatin, Rosuvastatin, and Fexofenadine**—Morepen has a presence in **82 countries**, backed by an annual API manufacturing capacity of **144 metric tons**. Its integrated capabilities across the pharmaceutical value chain give it a unique competitive edge in both regulated and emerging markets like the **US, Europe, Japan, China, and Russia**.

With a current formulation business size of approximately **₹325 crore**, the company is now accelerating toward a **₹1,000 crore target** over the next five years—driven by deeper market penetration, an expanded field force, and a growing portfolio of **cost-efficient, globally compliant therapies**.



MOREPEN
The Joy Of Growing Together

**Morepen
Doubles
Down on Rx
Innovation**

R_x

- **Ticapen**
Ticagrelor 60mg/90mg
- **Udofix**
Ursodeoxycholic Acid 150/300mg
- **Lycomore**
Lycopene 200ml
- **Acifix Raft**
Sodium Alginate 250mg, Sodium Bicarbonate 133.5 mg,
Calcium Carbonate 80mg

NEW ARRIVAL



India's pharmaceutical sector is poised to reach **\$130 billion by 2030**, and Morepen is strongly positioned to play a leading role in this transformation—strengthening domestic healthcare delivery while enhancing India's stature as the **Pharmacy of the World**.

New Product Highlights

Ticapen: Cardiovascular Care with Confidence

Ticapen (Ticagrelor 60mg/90mg) is a clinically proven, affordable antiplatelet therapy for ACS, Angina, and MI.

- Manufactured in USFDA-approved plants
- Unique 4x14 patient-compliant pack
- Day/Night adherence markers
- Premium matte foil packaging
- Competitively priced for widespread access

UdoFix: Setting New Standards in Liver Health

UdoFix (Ursodeoxycholic Acid 150/300mg) sets a new benchmark in hepatoprotective therapy with:

- 98.23% superior dissolution
- Anti-counterfeit Holosec packaging
- Manufactured in a USFDA-certified facility
- ₹39.9/tab pricing vs ₹57.1/tab for market leaders

LycoMore: Nutraceuticals Backed by Science

LycoMore Syrup blends Lycopene, essential vitamins, and minerals to support immunity and recovery.

- Glass bottle for enhanced shelf life
- Transparent red liquid with pleasant taste
- Dosing cap for convenience
- No foul odor; nutrient-rich formula

Acifix Raft: Fast Relief with a Flavor Patients Love

Acifix Raft Suspension offers targeted relief for GERD, reflux, and heartburn.

- Quick-acting, long-lasting raft mechanism
- Unique paan flavor for improved compliance
- Effective and patient-friendly solution for acid control

Strengthening Doctor Engagement and Market Reach

These new launches are part of a larger strategy to increase Morepen's presence across specialties and geographies through:

- **Nationwide awareness campaigns**
- **Specialty-focused CME programs**
- **Deeper collaboration with healthcare professionals (HCPs)**

With these additions and a focus on **in-house R&D, API strength, and clinical partnerships**, Morepen continues to lead with purpose—**making medicines that matter**, and making healthcare more **accessible, affordable, and effective** for millions of lives.